Allogeneic stem cell transplantation for sickle cell disease

Current Opinion in Hematology

Volumn 23, Issue 6, 2016, Pages 524-529

  Robinson, Tara M ^a   Fuchs, Ephraim J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

haploidentical donor; hematopoietic stem cell transplantation; sickle cell disease

Indexed keywords

HLA ANTIGEN;

ALLOGENEIC STEM CELL TRANSPLANTATION; CLINICAL TRIAL (TOPIC); DONOR; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HUMAN; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PATIENT SAFETY; PHENOTYPE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SIBLING; SICKLE CELL ANEMIA; TRANSPLANTATION CONDITIONING; ALLOTRANSPLANTATION; ANEMIA, SICKLE CELL; COMPLICATION; GENETICS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; MORTALITY; PROCEDURES; TREATMENT OUTCOME;

ANEMIA, SICKLE CELL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84982811826     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000282     Document Type: Review

References (30)

1. McCurdy SR, Kanakry JA, Showel MM, et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood 2015; 125:3024-3031.
2. Bacigalupo A, Dominietto A, Ghiso A, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: An update. Bone Marrow Transplant 2015; 50 (Suppl):S37-S39.
3. Bashey A. Peripheral blood stem cells for T cell-replete nonmyeloablative hematopoietic transplants using posttransplant cyclophosphamide. Biol Blood Marrow Transplant 2014; 20:598-599.
4. Konuma T, Tsukada N, Kanda J, et al. Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stemcell and unrelated cord blood in patients 50 years or older. Am J Hematol 2016; 91:E284- E292.
5. Valcárcel D, Sierra J, Wang T, et al. One-antigen mismatched related versus HLA-matched unrelated donor hematopoietic stem cell transplantation in adults with acute leukemia: Center for International Blood and Marrow Transplant Research results in the era of molecular HLA typing. Biol Blood Marrow Transplant 2011; 17:640-648.
6. Hassell KL. Population estimates of sickle cell disease in the US. Am J Prev Med 2010; 38:S512-S521.
7. Lanzkron S, Carroll CP, Haywood C. Mortality rates and age at death from sickle cell disease: US. Public Health Rep 2013; 128:110-116.
8. Swanson ME, Grosse SD, Kulkarni R. Disability among individuals with sickle cell disease: Literature review from a public health perspective. Am J Prev Med 2011; 41:S390-S397.
9. Johnson FL, Look AT, Gockerman J, et al. Bone-marrow transplantation in a patient with sickle-cell anemia. N Engl J Med 1984; 311:780-783.
10. Walters MC, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med 1996; 335:369-376.
11. Panepinto JA, Walters MC, Carreras J, et al. Matched-related donor transplantation for sickle cell disease: Report from the Center for International Blood and Transplant Research. Br J Haematol 2007; 137:479-485.
12. Bernaudin F, Socié G, Kuentz M, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 2007; 110:2749-2756.
13. Dedeken L, Lê PQ, Azzi N, et al. Haematopoietic stem cell transplantation for severe sickle cell disease in childhood: A single centre experience of 50 patients. Br J Haematol 2014; 165:402-408.
14. García Morin M, Cela E, Garrido C, et al. Bone marrow transplant in patients with sickle cell anaemia. Experience in one centre. An Pediatr (Barc) 2016. doi:10.1016/j.anpedi.2016.03.014.
15. Dallas MH, Triplett B, Shook DR, et al. Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant 2013; 19:820-830.
16. Vermylen C, Cornu G, Ferster A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: The first 50 patients transplanted in Belgium. Bone Marrow Transplant 1998; 22:1-6.
17. Brachet C, Azzi N, Demulder A, et al. Hydroxyurea treatment for sickle cell disease: Impact on haematopoietic stem cell transplantation's outcome. Bone Marrow Transplant 2004; 33:799-803.
18. Lederman HM, Connolly MA, Kalpatthi R, et al. Immunologic effects of hydroxyurea in sickle cell anemia. Pediatrics 2014; 134:686-695.
19. Krishnamurti L, Kharbanda S, Biernacki MA, et al. Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant 2008; 14:1270-1278.
20. Hsieh MM, Fitzhugh CD, Weitzel RP, et al. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA 2014; 312:48-56.
21. Horan JT, Haight A, Dioguardi JL, et al. Using fludarabine to reduce exposure to alkylating agents in children with sickle cell disease receiving busulfan, cyclophosphamide, and antithymocyte globulin transplant conditioning: Results of a dose de-escalation trial. Biol Blood Marrow Transplant 2015; 21:900-905.
22. Iannone R, Casella JF, Fuchs EJ, et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant 2003; 9:519-528.
23. Kamani NR, Walters MC, Carter S, et al. Unrelated donor cord blood transplantation for children with severe sickle cell disease: Results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant 2012; 18:1265- 1272.
24. Bolan'os-Meade J, Fuchs EJ, Luznik L, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood 2012; 120:4285-4291.
25. Mentzer WC, Heller S, Pearle PR, et al. Availability of related donors for bone marrow transplantation in sickle cell anemia. Am J Pediatr Hematol Oncol 1994; 16:27-29.
26. Elchuri SV, Williamson RS, Clark Brown R, et al. The effects of hydroxyurea and bone marrow transplant on Anti-Müllerian hormone (AMH) levels in females with sickle cell anemia. Blood Cells Mol Dis 2015; 55:56-61.
27. Walters MC, Hardy K, Edwards S, et al. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant 2010; 16:263-272.
28. Lavery SA, Islam R, Hunt J, et al. The medical and ethical challenges of fertility preservation in teenage girls: A case series of sickle cell anaemia patients prior to bone marrow transplant. Hum Reprod 2016. doi:10.1093/humrep/dew084.
29. Raiola AM, Dominietto A, Di Grazia C, et al. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant 2014; 20:1573-1579.
30. Solomon SR, Sanacore M, Zhang X, et al. Calcineurin inhibitor - free graftversus-host disease prophylaxis with posttransplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2014; 20:1828-1834.